91 related articles for article (PubMed ID: 12415634)
21. Synthesis and preclinical investigation of
Shah SQ; Gul-E-Raana
Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
[TBL] [Abstract][Full Text] [Related]
22. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
[TBL] [Abstract][Full Text] [Related]
23. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
[TBL] [Abstract][Full Text] [Related]
25. Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation.
Tian XX; Lam PY; Chen J; Pang JC; To SS; Di-Tomaso E; Ng HK
Neuropathol Appl Neurobiol; 1998 Oct; 24(5):389-96. PubMed ID: 9821170
[TBL] [Abstract][Full Text] [Related]
26. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
27. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
28. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
29. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells.
Alper O; De Santis ML; Stromberg K; Hacker NF; Cho-Chung YS; Salomon DS
Int J Cancer; 2000 Nov; 88(4):566-74. PubMed ID: 11058872
[TBL] [Abstract][Full Text] [Related]
30. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
32. Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.
Liu F; Du J; Xian J; Liu Y; Liu S; Lin Y
Am J Otolaryngol; 2015; 36(6):763-71. PubMed ID: 26545468
[TBL] [Abstract][Full Text] [Related]
33. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
36. Intraoperative therapy with liposomal drug delivery: retention and distribution in human head and neck squamous cell carcinoma xenograft model.
Wang SX; Bao A; Phillips WT; Goins B; Herrera SJ; Santoyo C; Miller FR; Otto RA
Int J Pharm; 2009 May; 373(1-2):156-64. PubMed ID: 19429301
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic effect of EGFR antisense cDNA on rat C6 gliomas in vivo].
Liu X; Pu P; Wang G
Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):422-4. PubMed ID: 10920933
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.
Brader KR; Wolf JK; Chakrabarty S; Price JE
Oncol Rep; 1998; 5(5):1269-74. PubMed ID: 9683849
[TBL] [Abstract][Full Text] [Related]
40. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
